Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
Conditions:  ARID1A Gene Mutation;  ATM Gene Mutation;  ATR Gene Mutation;  Bile Duct Adenocarcinoma;  BRCA1 Gene Mutation;  BRCA2 Gene Mutation;  BRIP1 Gene Mutation;  CHEK2 Gene Mutation;  EMSY Gene Mutation;  Fanconi Anemia Complementation Group Gene Mutation;  Metast atic Bile Duct Carcinoma;  MRE11 Gene Mutation;  NBN Gene Mutation;  PALB2 Gene Mutation;  PTEN Gene Deletion;  RAD51 Gene Mutation Intervention:  Drug: Olaparib Sponsors:  Academic and Community Cancer Research United;  National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Anemia | Cancer | Cancer & Oncology | Carcinoma | Faconi Anemia | Gastroschisis Repair | Genetics | Research